Disruption of the TGFβ-SMAD signaling pathway due to mutations in SMAD proteins has been described in relation to hrHPV infections of the cervix, cancers of the female reproductive system, including breast cancer, ovarian cancer and cervical cancer, and other cancers. This evidence concerns the gene TGFB1 and breast carcinoma.